Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
You may also be interested in...
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.
Without Otezla’s $2.2bn in 2020 sales, Amgen’s full-year revenue would have been slightly lower than in 2019, which is why all eyes are on the company’s R&D programs and near-term approvals.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.